Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lymphoblastic Lymphoma: early-phase trial registry
14 of 22 indexed Lymphoblastic Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #756 of 28,707 conditions by registered trial count.
22 US clinical trials · 14 currently recruiting · #756 of 28,707 conditions by registered trial count
Lymphoblastic Lymphoma: 22 US clinical trials tracked, 14 recruiting.
Lymphoblastic Lymphoma is the subject of 22 registered US clinical trials on ClinicalTrials.gov, 14 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is City of Hope Medical Center, running 5 of these trials.
Enrollment posture brief
Registry condition lymphoblastic-lymphoma
OPEN 14 | RECR 64% | LATE 2 | EARLY 13 | RANK #756 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Autoimmune Disease (64% recruiting · 11 trials)
Lymphoblastic Lymphoma lists 14 open slots (64% of 22 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lymphoblastic Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lymphoblastic Lymphoma is recruiting above its size-band peers.
14 of 22 indexed trials (63.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Lymphoblastic Lymphoma research.
City of Hope Medical Center accounts for 5 of 22 trials (22.7%). 15 distinct sponsors appear on at least one study for this condition label.
-
Typical Lymphoblastic Lymphoma enrolment sits around 102 participants.
Median target enrolment is 102 among the 22 trials that report a genuine target (sentinel values excluded). 11 of those (50%) plan for fewer than 100 participants.
-
Lymphoblastic Lymphoma research is mostly interventional.
20 interventional and 2 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
22 total, page 1 of 1
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
St. Jude Children's Research Hospital
NCT06289673
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
Children's Oncology Group
NCT05602194
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Children's Oncology Group
NCT01790152
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
National Cancer Institute (NCI)
NCT06364423
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
NCT06533748
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Wugen
NCT06514794
Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia
Northwestern University
NCT03932903
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
NCT04195633
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
NCT05476770
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
City of Hope Medical Center
NCT06918431
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
Children's Hospital of Philadelphia
NCT03810196
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
Medical College of Wisconsin
NCT05794880
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
University of Washington
NCT07224100
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
University of Chicago
NCT06207123
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
Dana-Farber Cancer Institute
NCT01177527
A High Intensity Electronic Health Intervention for the Reduction of Learning Disparities in Childhood Cancer Survivors
City of Hope Medical Center
NCT05428176
SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma
Dana-Farber Cancer Institute
NCT01574274
High-Intensity Parent Intervention Program in Improving Learning and School Functioning in Latino Children With Acute Leukemia or Lymphoblastic Lymphoma
City of Hope Medical Center
NCT03178617
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
City of Hope Medical Center
NCT02506933
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
City of Hope Medical Center
NCT04060277
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
Beam Therapeutics
NCT05885464
A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT01184885
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 8 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Lymphoblastic Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lymphoblastic Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lymphoblastic Lymphoma page
22 registered trials, 14 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 14 Lymphoblastic Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- City of Hope Medical Center sponsors the most Lymphoblastic Lymphoma trials on record, review their full trial history before evaluating a specific study. See City of Hope Medical Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphoblastic Lymphoma condition card totals 22 registered trials; most-linked intervention Vincristine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.